search
Back to results

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation (MHALT)

Primary Purpose

Cirrhosis, End Stage Liver Disease, Acute Kidney Injury

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Esophageal cooling/warming device
Mild hypothermia
Normothermia
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cirrhosis focused on measuring Hypothermia, NGAL - Neutrophil Gelatinase-associated Lipocalin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Liver transplantation from a donor after neurologic determination of death

Exclusion Criteria:

  • Liver transplantation from a donor after cardiac death
  • Acute liver failure
  • Living-donor liver transplantation
  • Simultaneous liver-kidney transplantation
  • Preoperative renal replacement therapy
  • Preoperative intubation
  • Portopulmonary hypertension
  • Machine perfusion of liver graft

Sites / Locations

  • University of California, San FranciscoRecruiting
  • University of Colorado Anschutz Medical CampusRecruiting
  • Houston Methodist Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Mild hypothermia & Esophageal cooling/warming device

Normothermia & Esophageal cooling/warming device

Arm Description

The target core temperature is 34-35 °C.

The target core temperature is 36.5-37.5 °C.

Outcomes

Primary Outcome Measures

Incidence of Acute Kidney Injury (AKI)
The International Club for Ascites (ICA) 2015 criteria, a revision of the Kidney Disease Improving Global Outcome (KDIGO) criteria for patients with cirrhosis, will be used to define AKI. A predefined subgroup analysis of this primary outcome will be performed in patients undergoing liver transplantation for hepatocellular carcinoma (HCC) with Model for End-stage Liver Disease exception points.

Secondary Outcome Measures

Distribution of the Stages of Acute Kidney Injury (AKI)
The International Club for Ascites (ICA) 2015 criteria, a revision of the Kidney Disease Improving Global Outcome (KDIGO) criteria for patients with cirrhosis, will be used to define the stage of AKI (Stage 1, 2, or 3). A predefined subgroup analysis of this secondary outcome will be performed in patients undergoing liver transplantation for hepatocellular carcinoma (HCC) with Model for End-stage Liver Disease exception points.
Duration of intensive care unit (ICU) stay
Time after liver transplantation until patient is discharged from the ICU to a regular hospital bed.
Duration of hospital stay
From the date of liver transplantation until the date patient is discharged from the hospital.
Patient survival
From the date of liver transplantation until the date of death from any cause.
Need for renal replacement therapy
Patient is receiving continuous renal replacement therapy or dialysis at the time of follow-up.
Persistent renal dysfunction
Presence of a reduction in GFR by ≥ 25 mL/min or ≥ 50% from baseline at the time of follow-up.
Serum neutrophil gelatinase-associated lipocalin (NGAL)
Change in serum NGAL levels from baseline to 2 hours after reperfusion of the portal vein.
Urine neutrophil gelatinase-associated lipocalin (NGAL)
Change in urine NGAL levels from baseline to 2 hours after reperfusion of the portal vein.

Full Information

First Posted
April 27, 2018
Last Updated
January 20, 2023
Sponsor
University of California, San Francisco
Collaborators
University of Colorado, Denver, The Methodist Hospital Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT03534141
Brief Title
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acronym
MHALT
Official Title
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation (MHALT) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 7, 2018 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
University of Colorado, Denver, The Methodist Hospital Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies). Patients who experience AKI after liver transplantation have higher mortality, increased graft loss, longer hospital and intensive care unit stays, and more progression to chronic kidney disease compared with those who do not. In this study, half of the participants will have their body temperature cooled to slightly lower than normal (mild hypothermia) for a portion of the liver transplant operation, while the other half will have their body temperature maintained at normal. The study will evaluate if mild hypothermia protects from AKI during liver transplantation.
Detailed Description
This study is a single-blinded, randomized controlled trial of mild hypothermia during liver transplantation to provide protection from AKI. Participants will be randomized to normothermia (36.5-37.5 °C) versus mild hypothermia (34-35 °C) during a portion of the liver transplant operation. The protocol is based on preliminary data from rodent models showing that hypothermia protects the kidneys from ischemia-reperfusion injury, as well as studies in deceased organ donors showing that cooling improves post-transplant organ function. Temperature will be maintained with standard techniques plus a minimally-invasive esophageal cooling device that is approved by the U.S. Food and Drug Administration. The investigators hypothesize that mild hypothermia will reduce the incidence and severity of AKI after LTx. Standard surrogates (e.g., change in serum creatinine, need for initiation of dialysis) and biomarkers will be used to assess the severity of kidney injury.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Keywords
Hypothermia, NGAL - Neutrophil Gelatinase-associated Lipocalin

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
230 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Mild hypothermia & Esophageal cooling/warming device
Arm Type
Experimental
Arm Description
The target core temperature is 34-35 °C.
Arm Title
Normothermia & Esophageal cooling/warming device
Arm Type
Active Comparator
Arm Description
The target core temperature is 36.5-37.5 °C.
Intervention Type
Device
Intervention Name(s)
Esophageal cooling/warming device
Other Intervention Name(s)
EnsoETM, ECD - Esophageal Cooling Device
Intervention Description
The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
Intervention Type
Other
Intervention Name(s)
Mild hypothermia
Intervention Description
Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
Intervention Type
Other
Intervention Name(s)
Normothermia
Intervention Description
After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
Primary Outcome Measure Information:
Title
Incidence of Acute Kidney Injury (AKI)
Description
The International Club for Ascites (ICA) 2015 criteria, a revision of the Kidney Disease Improving Global Outcome (KDIGO) criteria for patients with cirrhosis, will be used to define AKI. A predefined subgroup analysis of this primary outcome will be performed in patients undergoing liver transplantation for hepatocellular carcinoma (HCC) with Model for End-stage Liver Disease exception points.
Time Frame
72 hours from the end of surgery
Secondary Outcome Measure Information:
Title
Distribution of the Stages of Acute Kidney Injury (AKI)
Description
The International Club for Ascites (ICA) 2015 criteria, a revision of the Kidney Disease Improving Global Outcome (KDIGO) criteria for patients with cirrhosis, will be used to define the stage of AKI (Stage 1, 2, or 3). A predefined subgroup analysis of this secondary outcome will be performed in patients undergoing liver transplantation for hepatocellular carcinoma (HCC) with Model for End-stage Liver Disease exception points.
Time Frame
72 hours from the end of surgery
Title
Duration of intensive care unit (ICU) stay
Description
Time after liver transplantation until patient is discharged from the ICU to a regular hospital bed.
Time Frame
up to 1 year
Title
Duration of hospital stay
Description
From the date of liver transplantation until the date patient is discharged from the hospital.
Time Frame
up to 1 year
Title
Patient survival
Description
From the date of liver transplantation until the date of death from any cause.
Time Frame
up to 1 year
Title
Need for renal replacement therapy
Description
Patient is receiving continuous renal replacement therapy or dialysis at the time of follow-up.
Time Frame
7 days, 30 days, and 1 year
Title
Persistent renal dysfunction
Description
Presence of a reduction in GFR by ≥ 25 mL/min or ≥ 50% from baseline at the time of follow-up.
Time Frame
90 days and 1 year
Title
Serum neutrophil gelatinase-associated lipocalin (NGAL)
Description
Change in serum NGAL levels from baseline to 2 hours after reperfusion of the portal vein.
Time Frame
Baseline (start of surgery) and 2 hours after reperfusion of the portal vein
Title
Urine neutrophil gelatinase-associated lipocalin (NGAL)
Description
Change in urine NGAL levels from baseline to 2 hours after reperfusion of the portal vein.
Time Frame
Baseline (start of surgery) and 2 hours after reperfusion of the portal vein
Other Pre-specified Outcome Measures:
Title
Blood product transfusions
Description
The number of units of packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate transfused during the perioperative period.
Time Frame
72 hours from the end of surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Liver transplantation from a donor after neurologic determination of death Exclusion Criteria: Liver transplantation from a donor after cardiac death Acute liver failure Living-donor liver transplantation Simultaneous liver-kidney transplantation Preoperative renal replacement therapy Preoperative intubation Portopulmonary hypertension Machine perfusion of liver graft
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael P Bokoch, MD, PhD
Phone
(415) 476-8389
Email
Michael.Bokoch@ucsf.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Claus U Niemann, MD
Phone
(415) 502-2162
Email
Claus.Niemann@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael P Bokoch, MD, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael P Bokoch, MD, PhD
Phone
415-476-8389
Email
Michael.Bokoch@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Claus U Niemann, MD
Phone
(415) 502-2162
Email
Claus.Niemann@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Michael P Bokoch, MD, PhD
First Name & Middle Initial & Last Name & Degree
Claus U Niemann, MD
First Name & Middle Initial & Last Name & Degree
Dieter Adelmann, MD, PhD
Facility Name
University of Colorado Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trevor L Nydam, MD
Phone
720-848-0833
Email
Trevor.Nydam@ucdenver.edu
First Name & Middle Initial & Last Name & Degree
Ana Fernandez-Bustamante, MD
Phone
(720) 848-6709
Email
ANA.FERNANDEZ-BUSTAMANTE@CUANSCHUTZ.EDU
First Name & Middle Initial & Last Name & Degree
Trevor L Nydam, MD
First Name & Middle Initial & Last Name & Degree
Ana Fernandez-Bustamante, MD PhD
Facility Name
Houston Methodist Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Terminated

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26222557
Citation
Niemann CU, Feiner J, Swain S, Bunting S, Friedman M, Crutchfield M, Broglio K, Hirose R, Roberts JP, Malinoski D. Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function. N Engl J Med. 2015 Jul 30;373(5):405-14. doi: 10.1056/NEJMoa1501969.
Results Reference
background
PubMed Identifier
25631669
Citation
Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G; International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015 Apr;64(4):531-7. doi: 10.1136/gutjnl-2014-308874. Epub 2015 Jan 28. No abstract available.
Results Reference
background
PubMed Identifier
19938135
Citation
Niemann CU, Walia A, Waldman J, Davio M, Roberts JP, Hirose R, Feiner J. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl. 2009 Dec;15(12):1852-60. doi: 10.1002/lt.21938.
Results Reference
background
PubMed Identifier
29283916
Citation
Kalasbail P, Makarova N, Garrett F, Sessler DI. Heating and Cooling Rates With an Esophageal Heat Exchange System. Anesth Analg. 2018 Apr;126(4):1190-1195. doi: 10.1213/ANE.0000000000002691.
Results Reference
background
PubMed Identifier
25420865
Citation
Karapanagiotou A, Dimitriadis C, Papadopoulos S, Kydona C, Kefsenidis S, Papanikolaou V, Gritsi-Gerogianni N. Comparison of RIFLE and AKIN criteria in the evaluation of the frequency of acute kidney injury in post-liver transplantation patients. Transplant Proc. 2014 Nov;46(9):3222-7. doi: 10.1016/j.transproceed.2014.09.161.
Results Reference
background
PubMed Identifier
28255614
Citation
Kellum JA, Zarbock A, Nadim MK. What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Med. 2017 Jun;43(6):901-903. doi: 10.1007/s00134-017-4732-1. Epub 2017 Mar 2. No abstract available.
Results Reference
background

Learn more about this trial

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

We'll reach out to this number within 24 hrs